Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


Predicting T cell recognition of MHC class I restricted neoepitopes.

Koşaloğlu-Yalçın Z, Lanka M, Frentzen A, Logandha Ramamoorthy Premlal A, Sidney J, Vaughan K, Greenbaum J, Robbins P, Gartner J, Sette A, Peters B.

Oncoimmunology. 2018 Aug 27;7(11):e1492508. doi: 10.1080/2162402X.2018.1492508. eCollection 2018.


Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis.

Tsoneva D, Minev B, Frentzen A, Zhang Q, Wege AK, Szalay AA.

Mol Ther Oncolytics. 2017 Mar 21;5:41-61. doi: 10.1016/j.omto.2017.03.001. eCollection 2017 Jun 16.


Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.

Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, Lou E, Fujisawa S, Eveno C, Belin L, Zanzonico P, Szalay A, Fong Y.

Breast Cancer Res Treat. 2016 Apr;156(3):607-608. doi: 10.1007/s10549-016-3767-2. No abstract available.


Drug-Encoded Biomarkers for Monitoring Biological Therapies.

Tsoneva D, Stritzker J, Bedenk K, Zhang Q, Frentzen A, Cappello J, Fischer U, Szalay AA.

PLoS One. 2015 Sep 8;10(9):e0137573. doi: 10.1371/journal.pone.0137573. eCollection 2015.


Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.

Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA.

Viruses. 2015 Jul 20;7(7):4075-92. doi: 10.3390/v7072811.


Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring.

Frentzen A, Geissinger U, Tsoneva D, Stritzker J.

Methods Mol Biol. 2015;1317:225-37. doi: 10.1007/978-1-4939-2727-2_13.


Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons.

Anggakusuma, Frentzen A, Gürlevik E, Yuan Q, Steinmann E, Ott M, Staeheli P, Schmid-Burgk J, Schmidt T, Hornung V, Kuehnel F, Pietschmann T.

J Virol. 2015 Apr;89(7):3833-45. doi: 10.1128/JVI.03129-14. Epub 2015 Jan 21.


Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.

Huang T, Wang H, Chen NG, Frentzen A, Minev B, Szalay AA.

Mol Ther Oncolytics. 2015 Mar 18;2:15003. doi: 10.1038/mto.2015.3. eCollection 2015.


A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.

Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, Lou E, Fujisawa S, Eveno C, Belin L, Zanzonico P, Szalay A, Fong Y.

Breast Cancer Res Treat. 2014 Dec;148(3):489-99. doi: 10.1007/s10549-014-3180-7. Epub 2014 Nov 13. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(3):607-8.


Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

Adelfinger M, Gentschev I, Grimm de Guibert J, Weibel S, Langbein-Laugwitz J, Härtl B, Murua Escobar H, Nolte I, Chen NG, Aguilar RJ, Yu YA, Zhang Q, Frentzen A, Szalay AA.

PLoS One. 2014 Aug 5;9(8):e104337. doi: 10.1371/journal.pone.0104337. eCollection 2014.


Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.

Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T.

J Virol. 2014 Feb;88(3):1433-46. doi: 10.1128/JVI.01815-13. Epub 2013 Oct 30.


Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment.

Steinmann E, Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Hillung J, Gentzsch J, Lauber C, Brown R, Frentzen A, Pietschmann T.

J Virol. 2013 Dec;87(24):13297-306. doi: 10.1128/JVI.01708-13. Epub 2013 Oct 2.


Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.

Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E.

Gut. 2014 Jul;63(7):1137-49.


Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.

Frentzen A, Anggakusuma, Gürlevik E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kröger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T.

Hepatology. 2014 Jan;59(1):78-88. doi: 10.1002/hep.26626. Epub 2013 Nov 18.


Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.

Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, Ehrig K, Stritzker J, Mundt AJ, Szalay AA.

Int J Cancer. 2013 Dec 15;133(12):2989-99. doi: 10.1002/ijc.28296. Epub 2013 Aug 5.


hepatitis c Virus p7 is critical for capsid assembly and envelopment.

Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G, Perin PM, Frentzen A, Kaderali L, Pietschmann T.

PLoS Pathog. 2013;9(5):e1003355. doi: 10.1371/journal.ppat.1003355. Epub 2013 May 2.


Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.

Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A, Gentschev I, Jakob PM, Szalay AA.

J Transl Med. 2013 May 1;11:106. doi: 10.1186/1479-5876-11-106.


Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.

Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA.

Bioengineered. 2013 Mar-Apr;4(2):84-9. doi: 10.4161/bioe.22462. Epub 2012 Oct 23.


Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, Nolte I, Frentzen A, Szalay AA.

PLoS One. 2012;7(10):e47472. doi: 10.1371/journal.pone.0047472. Epub 2012 Oct 16.


MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles.

Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T.

PLoS Pathog. 2012;8(7):e1002829. doi: 10.1371/journal.ppat.1002829. Epub 2012 Jul 26.


Two methods of heterokaryon formation to discover HCV restriction factors.

Frentzen A, Hueging K, Bitzegeio J, Pietschmann T, Steinmann E.

J Vis Exp. 2012 Jul 16;(65):e4029. doi: 10.3791/4029.


Bile acids specifically increase hepatitis C virus RNA-replication.

Chhatwal P, Bankwitz D, Gentzsch J, Frentzen A, Schult P, Lohmann V, Pietschmann T.

PLoS One. 2012;7(4):e36029. doi: 10.1371/journal.pone.0036029. Epub 2012 Apr 25.


Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines.

Heisig M, Frentzen A, Bergmann B, Galmbacher K, Gentschev I, Hotz C, Schoen C, Stritzker J, Fensterle J, Rapp UR, Goebel W.

BMC Microbiol. 2011 Jul 11;11:163. doi: 10.1186/1471-2180-11-163.


Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines.

Frentzen A, Hüging K, Bitzegeio J, Friesland M, Haid S, Gentzsch J, Hoffmann M, Lindemann D, Zimmer G, Zielecki F, Weber F, Steinmann E, Pietschmann T.

PLoS Pathog. 2011 Apr;7(4):e1002029. doi: 10.1371/journal.ppat.1002029. Epub 2011 Apr 28.


Streptococcus pneumoniae evades human dendritic cell surveillance by pneumolysin expression.

Littmann M, Albiger B, Frentzen A, Normark S, Henriques-Normark B, Plant L.

EMBO Mol Med. 2009 Jul;1(4):211-22. doi: 10.1002/emmm.200900025.


Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.

Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12915-20. doi: 10.1073/pnas.0900660106. Epub 2009 Jul 15.


Listeria monocytogenes as novel carrier system for the development of live vaccines.

Schoen C, Loeffler DI, Frentzen A, Pilgrim S, Goebel W, Stritzker J.

Int J Med Microbiol. 2008 Jan;298(1-2):45-58. Epub 2007 Oct 23. Review.


Supplemental Content

Loading ...
Support Center